azelnidipine has been researched along with angiotensin ii in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, TX; Horiuchi, M; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Suzuki, J; Tsuda, M | 1 |
| Abe, Y; Hara, T; Hitomi, H; Kimura, S; Kiyomoto, H; Kohno, M; Kondo, N; Miyatake, A; Moriwaki, K; Nishiyama, A; Rahman, M; Sun, GP; Yamamoto, T | 1 |
| Inoue, H; Kikuchi, S; Matsui, T; Nakamura, K; Yamagishi, S | 1 |
| Ikeda, K; Inada, Y; Isaka, T; Tajima, N; Takada, Y; Tojo, K | 1 |
| Fujimoto, S; Horike, H; Kashihara, N; Nagasu, H; Sasaki, T; Satoh, M | 1 |
| Geot, WM; Horikoshi, S; Suzuki, Y; Takahashi, H; Tanifuji, C; Tomino, Y | 1 |
| Horiguchi, N; Ichikawa, T; Izumi, T; Kakizaki, S; Kishimoto, K; Mori, M; Ohyama, T; Sato, K; Takagi, H; Yamazaki, Y | 1 |
| Hirata, Y; Kitagawa, T; Kurobe, H; Matsuoka, Y; Maxfield, MW; Sata, M; Sugasawa, N | 1 |
| Jiang, D; Kato, J; Kawagoe, Y; Kitamura, K; Kuwasako, K | 1 |
| Asada, Y; Jiang, D; Kaikita, K; Kato, J; Kawagoe, Y; Kitamura, K; Matsuzaki, M; Tsuruda, T | 1 |
10 other study(ies) available for azelnidipine and angiotensin ii
| Article | Year |
|---|---|
Effect of azelnidipine on angiotensin II-mediated growth-promoting signaling in vascular smooth muscle cells.
Topics: Angiotensin II; Animals; Aorta, Thoracic; Azetidinecarboxylic Acid; Cells, Cultured; Dihydropyridines; Dose-Response Relationship, Drug; MAP Kinase Signaling System; Muscle, Smooth, Vascular; Rats; Rats, Sprague-Dawley | 2005 |
Effects of calcium channel blockade on angiotensin II-induced peritubular ischemia in rats.
Topics: Adenosine Triphosphate; Angiotensin II; Animals; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Ischemia; Kidney Tubules; Male; Rats; Rats, Sprague-Dawley; Vascular Resistance | 2006 |
Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells.
Topics: Angiotensin II; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cells, Cultured; Dihydropyridines; Endothelial Cells; Eye Proteins; Gene Expression Regulation; Humans; Microcirculation; Nerve Growth Factors; Nitrendipine; Oxidative Stress; Reactive Oxygen Species; RNA, Messenger; Serpins | 2005 |
Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocortical cell line NCI-H295R.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Aldosterone; Angiotensin II; Azetidinecarboxylic Acid; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cell Line, Tumor; Cytochrome P-450 CYP11B2; Dihydropyridines; Gene Expression Regulation; Humans; Nitrophenols; Organophosphorus Compounds; Potassium Chloride; Steroid 11-beta-Hydroxylase | 2009 |
Azelnidipine exerts renoprotective effects by improvement of renal microcirculation in angiotensin II infusion rats.
Topics: Angiotensin II; Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; Dihydropyridines; Infusions, Intravenous; Male; Microcirculation; Nephritis, Interstitial; Nifedipine; Rats; Rats, Wistar; Renal Circulation | 2009 |
Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Azetidinecarboxylic Acid; Blotting, Western; Calcium Channel Blockers; Dihydropyridines; Drug Synergism; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Imidazoles; Immunohistochemistry; Kidney; Mice; NADPH Oxidases; Nitric Oxide Synthase Type III; Polycystic Kidney Diseases; Tetrazoles | 2009 |
Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence.
Topics: Angiotensin II; Animals; Antioxidants; Azetidinecarboxylic Acid; Calcium; Calcium Channel Blockers; Carbon Tetrachloride; Cell Line; Cell Survival; Collagen Type I; Collagen Type I, alpha 1 Chain; Dihydropyridines; Disease Models, Animal; Gene Expression Regulation; Humans; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Reactive Oxygen Species; RNA, Messenger; Thioacetamide; Transforming Growth Factor beta1 | 2012 |
Azelnidipine suppresses the progression of aortic aneurysm in wild mice model through anti-inflammatory effects.
Topics: Aminopropionitrile; Angiotensin II; Animals; Anti-Inflammatory Agents; Aorta, Abdominal; Aorta, Thoracic; Aortic Aneurysm, Abdominal; Aortic Aneurysm, Thoracic; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Disease Models, Animal; Disease Progression; Inflammation Mediators; Macrophages; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Sirtuin 1; Time Factors; Tumor Necrosis Factor-alpha | 2013 |
Inhibitory effects of losartan and azelnidipine on augmentation of blood pressure variability induced by angiotensin II in rats.
Topics: Angiotensin II; Animals; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Dose-Response Relationship, Drug; Hypertension; Losartan; Male; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Time Factors | 2017 |
Analysis of Mechanisms for Increased Blood Pressure Variability in Rats Continuously Infused with Angiotensin II.
Topics: Angiotensin II; Animals; Blood Pressure; Hypertension; Male; Rats; Rats, Wistar | 2023 |